Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies
NCT ID: NCT05598788
Last Updated: 2023-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
360 participants
OBSERVATIONAL
2023-03-03
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
NCT04823923
A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
NCT04056455
The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer
NCT02404584
Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer
NCT02751827
Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
NCT03571438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measurement of drug concentrations
Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* person who does not object to their participation in the research
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
VERDIER Marie-Clemence
Role: PRINCIPAL_INVESTIGATOR
Rennes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Eugène Marquis Unicancer
Rennes, , France
Rennes University Hospital
Rennes, , France
Institut de cancérologie Strasbourg Europe
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Le Du Fanny
Role: primary
LIEVRE Astrid
Role: primary
BARTHELEMY Philippe
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35RC22_8962_MISTIK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.